title: Plasma adrenomedullin and obstructive sleep apnea.
abstract: BACKGROUND
  Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances.
  
  
  METHODS
  Plasma ADM levels were measured at 9:30 PM, 2:00 AM (after 4 to 5 h of untreated OSA), and 6:00 AM (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls.
  
  
  RESULTS
  Baseline ADM levels were similar in the OSA and control groups (28.7 +/- 6.7 v 27.7 +/- 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure.
  
  
  CONCLUSIONS
  OSA does not exert any significant acute or chronic effects on plasma ADM levels.
authors.affiliation: Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Wolk
authors.forename: Anna
authors.initials: A
authors.lastname: Svatikova
authors.forename: Maria E
authors.initials: ME
authors.lastname: Otto
authors.forename: Michal S
authors.initials: MS
authors.lastname: Hoffmann
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Duenwald
authors.forename: Virend K
authors.initials: VK
authors.lastname: Somers
mesh_terms: D053607:Adrenomedullin; D000328:Adult; D015992:Body Mass Index; D045422:Continuous Positive Airway Pressure; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D017286:Polysomnography; D020181:Sleep Apnea, Obstructive / Q000097:blood* / Q000150:complications / Q000628:therapy
chemical_list: D010455:Peptides; D053607:Adrenomedullin